Not Yet RecruitingPhase 2ACTRN12605000689673
An initial factorial evaluation of the potential synergy between two novel agents (CB0011 and CB0012) for the treatment of Obstructive Sleep Apnea Syndrome
Sponsor
Cypress Bioscience, Inc
Enrollment
100 participants
Start Date
Sep 3, 2006
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and femalesMin Age: 21 Yearss
Inclusion Criteria1
- Subjects must have a current diagnosis of Obstructive Sleep Apnea Syndrome, have an apnea-hypopnea index (AHI) of between 10-40 (using a strict definition of hypopnea), with a calculated BMI equal or less than 40 at the time of study entry.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A four week 1:1:1:1:1 randomised study in patients with diagnosed Obstructive Sleep Apnea Syndrome. 100 completed patients, 20 to be randomised to CB0012 alone at two different sequential doses, 20 pa
A four week 1:1:1:1:1 randomised study in patients with diagnosed Obstructive Sleep Apnea Syndrome. 100 completed patients, 20 to be randomised to CB0012 alone at two different sequential doses, 20 patients to be randomised to 15mg of CB0011 and CB0012 at two different sequential doses, 20 patients to be randomised to 30mg of CB0011 and CB0012 at two different sequential doses, 20 patients to be randomised to CB0011 alone, and 20 patients to be randomised to placebo.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000689673